---
title: "Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285838804.md"
description: "Shanghai Henlius Biotech, Inc. has received FDA approval to conduct a phase 1 clinical trial for HLX05-N, a biosimilar to cetuximab, aimed at treating metastatic colorectal cancer. This follows prior approval from China's National Medical Products Administration. The company anticipates entering a lucrative oncology biosimilar market, with global sales projected at USD 1.66 billion by 2025. Analysts rate the stock as a Buy with a target price of HK$99.78, although successful development is not guaranteed."
datetime: "2026-05-10T10:38:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285838804.md)
  - [en](https://longbridge.com/en/news/285838804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285838804.md)
---

# Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.

Shanghai Henlius Biotech has received U.S. Food and Drug Administration approval for an investigational new drug application to conduct a phase 1 clinical trial of HLX05-N, a cetuximab biosimilar injection, for metastatic colorectal cancer. The company plans to initiate the trial in the United States once conditions are met, following earlier approval of a similar trial by China’s National Medical Products Administration.

HLX05-N is designed to mirror the reference cetuximab product in treating colorectal cancer and head and neck squamous cell carcinoma by targeting the epidermal growth factor receptor pathway. With global sales of cetuximab biosimilars reaching about USD 1.66 billion in 2025, the FDA green light positions Henlius to tap into a sizable oncology biosimilar market, although the company cautions that successful development and commercialization are not guaranteed.

The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

**More about Shanghai Henlius Biotech, Inc. Class H**

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing and commercializing biosimilar and biologic medicines. The company targets major oncology indications, including colorectal and head and neck cancers, aiming to expand its presence in global markets such as the United States.

**Average Trading Volume:** 1,016,057

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$39.97B

Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02696.HK](https://longbridge.com/en/quote/02696.HK.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial](https://longbridge.com/en/news/286246864.md)
- [TELUS launches inaugural biodiversity strategy and action plan](https://longbridge.com/en/news/287230122.md)
- [Henlius Grants New Share Options and RSUs to Align Incentives With Performance](https://longbridge.com/en/news/283152010.md)
- [Island Pharmaceuticals Strengthens Biodefence Engagement for Galidesivir Advancement](https://longbridge.com/en/news/286834766.md)
- [VN introduces biometric authentication for e-invoice procedures](https://longbridge.com/en/news/287182852.md)